Skip to main content
Dryad logo

Data from: Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis

Citation

Lexchin, Joel (2017), Data from: Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis, Dryad, Dataset, https://doi.org/10.5061/dryad.tv138

Abstract

Objectives Investigate if the recommendations by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) to provincial, territorial and federal drug plans about whether to list non-oncology and oncology drug-indication combinations on their formularies are associated with whether the drug-indication combination was approved via the standard evidence pathway or the Notice of Compliance with conditions (NOC/c – limited evidence) pathway. Design Cohort study. Data sources Web sites of the CDR and pCODR up to the end of March 31, 2017; journal articles evaluating drugs approved through the NOC/c pathway, the Notice of Compliance database, the Notice of Compliance with conditions web site and the Summary Basis of Decision website. Interventions Recommendations by the CDR and pCODR. Primary and secondary outcome measures Analysis of the percent of drugs receiving positive listing recommendations from CDR and pCODR depending on the pathway used to approve the drug. Results There were 310 recommendations for drug-indication combinations from the CDR and 79 from the pCODR. There was a statistically significant difference in the number of drug-indication combinations that received a list versus do not list recommendation from the CDR for those approved through the standard pathway compared to those approved through the NOC/c pathway (p = 0.0407). A similar analysis for recommendations from the pCODR was not statistically significant. Conclusion For non-oncology drug-indication combinations, the type of review appears to influence the recommendation regarding listing on public formularies. This difference may reflect the level of evidence about the efficacy and safety of the drug-indication at the time the recommendation was made.

Usage Notes

Location

Canada